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Case Summary. A 25-year-old caucasian lady presented to the Accident & Emergency department complaining of acute onset
severe epigastric pain radiating through to the back with associated nausea and vomiting. A diagnosis of acute pancreatitis was
made. Symptoms commenced after the third dose of Metronidazole therapy prescribed for a recurrent periodontal abscess. The
patient described a similar episode 10 months previously. On neither occasion were any other medications being taken, there was
no history of alcohol abuse and no other gastro-intestinal aetiology could be identiﬁed on imaging. Symptoms resolved quickly
upon discontinuation of the antibiotic agent. We conclude therefore that Metronidazole can reasonably be identiﬁed as the only
potential causative agent. Discussion. The proportion of cases of pancreatitis caused by drugs is estimated to be around 2% in
the general population. The exact mechanism of action of Metronidazole induced pancreatitis is unclear but a trigger role for
the drug seems likely. Conclusion. This case provides the eighth report of Metronidazole induced pancreatitis. All of the cases
were reported in females and ran a benign course.Early diagnosis, discontinuation of the drug and supportive care will lead to a
successful recovery in the majority of cases.
1.Introduction
Metronidazole is a nitroimidazole antibacterial medication
used mainly in the treatment of infections caused by
anaerobic bacteria and protozoa. It is commonly known by
the trade name Flagyl. Systemic Metronidazole is indicated
for the treatment of many anaerobic infections which
can clinically present as gynaecological conditions; bacte-
rial vaginosis, and abdominal conditions; Crohn’s disease,
necrotizing pancreatitis and gastritis. Metronidazole is also
commonlyprescribedinthetreatmentofacutegingivitisand
periodontal infections [1].
The adverse side eﬀects of Metronidazole include gas-
trointestinal upset, metallic taste [2], urticaria [3], headache,
peripheral neuropathy [2], and rarely pancreatitis. There are
only seven reported cases of Metronidazole-induced pancre-
atitis in the English language literature to date (Table 1).
Acute pancreatitis is an inﬂammatory disease with a wide
spectrum of severity [9]. It is clinically characterized by
acute constant abdominal pain [10] and elevated pancreatic
enzymes [10]. Alcoholism and biliary tract stone disease
account for 95% of cases [11]. Acute pancreatitis is classiﬁed
as mild, moderate, or severe, the diﬀerentiation of which
is made by using disease severity scores such as Imrie [9],
Ranson, and more recently APACHE II.
We report a case of recurrent mild-acute pancreatitis,
Imrie score I, associated with just 3 doses of Metronidazole
therapy prescribed for a periodontal abscess.
2.CaseReport
A 25-year-old caucasian lady presented to the Accident &
Emergency Department of a general hospital complaining of
acute onset severe epigastric pain radiating through to the
back with associated nausea and vomiting. History, exam-
ination and biochemical analysis conﬁrmed a diagnosis of
acute pancreatitis, Imrie score 1 [9]. Symptoms commenced
after the third dose of Metronidazole therapy prescribed by
the patient’s dentist for treatment of a periodontal abscess.
Amylase was 810 on admission and CRP was 70. CRP peaked
to 248 on day 4 and rapidly declined thereafter. Relative
negatives in the history included no other concurrent
medications, no known drug allergies, alcohol consumption
of 3–6 units weekly, and the patient was a nonsmoker.2 HPB Surgery
Table 1
Reference Age (years) Gender Episode
Metronidazole to
Pancreatitis
(interval in days)
Indications for Metronidazole
[3]2 9 Female 1 1 Postpartum unspeciﬁed vaginitis
2 37 Unspeciﬁed vaginitis
[4]6 3 F e m a l e 1 7 Crohn’s disease
[5]6 1 F e m a l e 1 4 Aspiration pneumonia
[6]4 9 Female 1 3–5 Trichomoniasis
2 Less than 1 Trichomoniasis
[7]2 3 Female 1 8 Bacterial vaginosis
2,3,4 3–7 Bacterial vaginosis
[8]2 2 Female 1 Less than 1 Unspeciﬁed vaginosis
2,3 1 Unspeciﬁed vaginosis
[2]4 6 Female 1 8 Bacterial vaginosis
2 8 Bacterial vaginosis
Our Case 25 Female 1 2E n d o d o n t i c a b s c e s s
2 1E n d o d o n t i c a b s c e s s
Relevant past surgical history included; (1) laparoscopic
cholecystectomy (June 2006) for symptomatic treatment of
suspectedbiliarycolicalthoughgallstoneswerenotidentiﬁed
on imaging and (2) ﬁrst episode of acute pancreatitis
requiring hospital admission (Septmber 2009) following 5
dosestoMetronidazoletherapyprescribedfordentalabscess.
Ultrasound scan, Computed Topography of abdomen,
and Endoscopic Retrograde Cholangio-Pancreatography all
failed to demonstrate gallstones as potential aetiology at that
time.
On this admission, a detailed history and biochemical
evaluation excluded other risk factors for pancreatitis-
gallstones, increased alcohol intake, recent ERCP, hypercal-
caemia, hypercholesterolaemia, or viral infections. She was
not taking any regular medications nor did she have any
known drug allergies. Imaging by ultrasound scan reported
previous cholecystectomy, normal common bile duct, and
once again no gallstones were visualized. Magnetic Reso-
nance Cholangio-Pancreatography also demonstrated nor-
mal intra- and extrahepatic biliary anatomy. These factors
combined with past surgical history provided convincing
evidence of Metronidazole as the most probable aetiological
factor.
Supportive management of IV ﬂuid resusitation, anal-
gesia, antiemetic and, nil per oral was instituted and
Metronidazole therapy was immediately discontinued. Her
clinical course was uncomplicated and amylase returned to
normal on day 4 post admission (Table 2). She began to
tolerate light diet on day 5 and was discharged on day 7.
3. Discussion
The proportion of cases of pancreatitis caused by drugs
is estimated to be around 2% in the general population,
with much higher proportions in high risk groups, such as
children and HIV positive patients [12].
Speciﬁc criteria to support drug-induced illness was
ﬁrst described by Mallory et al. in 1980; case reports with
the strongest evidence are those that (1) clearly diagnose
pancreatitis and exclude common aetiologies, (2) provide
the dose and time interval between the start of treatment
with thesuspected drug and the development of pancreatitis,
(3) document response to withdrawal of the drug, and (4)
demonstrate recurrent pancreatitis upon rechallenge with
the drug [13]. The majority of cases are mild [14], but severe
and even fatal cases of drug-induced pancreatitis may occur,
thus making identiﬁcation of the oﬀending agent critical
[12].
Although there are only 7 previous case reports of
Metronidazole-induced pancreatitis in the English literature,
the drug meets the above criteria and can be classiﬁed
as having a probable association with the onset of acute
pancreatitis [15, 16].
Our patient developed pancreatitis after the third dose
of Metronidazole on two diﬀerent isolated occasions 10
months apart. On neither occasion could any other aeti-
ology be identiﬁed, in particular gallstones were clearly
outruled by radiological imaging on both admissions and
symptoms resolved quickly upon discontinuation of the
antibiotic agent. We conclude therefore that Metronidazole
can reasonably be identiﬁed as the only potential causative
agent.
This case provides the eighth report of Metronidazole-
induced pancreatitis in the English language literature as
showninTable 1 [2].Allofthecaseswerereportedinfemales
and ran a benign course in continuity with most drug-
induced pancreatitis [14].
There was a variable interval between exposure to
Metronidazole and development of pancreatitis rangingHPB Surgery 3
Table 2: Progression of biochemical and haematological values during admission.
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Amylase (27–131U/L) 810 403 241 117 56 37 23
CRP (≤10mg/L) 70 131 242 248 166 101 16
WCC (4–10 ×109/L) 19.6 13.1 12.9 10.1 8.5 8.5 8.2
AST (15–41IU/L) 20 24 19 16 12 15 14
Glucose (4.4–5.6mmol/L) 5.4 4.9 3.7 3.5 4.9 4.2 3.8
Calcium (2.1–2.7mmol/L) 2.16
Albumin (35–50g/L) 41 30 32 31 29 29 32
Urea (2.1–6.4mmol/L) 3 2.2 1.6 1.4 1.5 1.1 2.7
Creatinine (39–91umol/L) 56 53 57 61 50 53 52
Hb (13–17g/dL) 13.3 11.2 11.2 11.9 11.1 10.9 11.8
from 12 hours [8]t o3 8d a y s[ 3], it should therefore be
considered in patients presenting after minimal exposure to
Metronidazole, in our case just 3 doses. A rechallenge is not
toberecommendedbutthisrequiresearlyrecognitiononthe
part of the clinician.
The mechanism of action of Metronidazole-induced
pancreatitisisunknownbutthehighincidenceofconcurrent
illnesses known to induce acute pancreatitis makes a trigger
role or cofactor role for the drug seem most likely [15].
One speculative mechanism of action is that under aerobic
conditions Metronidazole may undergo redox cycling and
yield hydrogen peroxide, superoxide, and other free radicals
which are toxic to the pancreatic beta cells and induce
pancreatitis [7]. It is interesting that due to good penetration
of Metronidazole in the pancreas and the degree of coverage
provided against the typical bacterial ﬂora of the pancreas
it is paradoxically indicated in the treatment of infected
pancreatic necrosis [17].
Severe pancreatitis requiring hospital admission appears
to be a rare adverse reaction [18]; however, in a recent
population-basedcase-controlstudyof3083casesand30830
controls, Metronidazole was associated with a threefold
increased risk of acute pancreatitis when used in combina-
tion with other drugs for H.Pylori eradication [19]. Like
any drug-induced reaction, management of Metronidazole
associatedacutepancreatitisrequiresquickwithdrawalofthe
oﬀending agent and supportive care [12].
4. Conclusion
Pancreatitis is a disease with a wide variety of aetiologies,
severity, complications, and outcomes. Metronidazole is
commonly used in the hospital and community setting as it
is a potent and eﬀective treatment for many anaerobic infec-
t i o n s .G Iu p s e ti saw e l l -d o c u m e n t e ds i d ee ﬀect of the drug.
The incidence of severe Metronidazole-induced pancreatitis
is relatively rare; however, it can cause serious morbidity
in patients after minimal exposure, and identiﬁcation of
Metronidazole as the causative agent is the key to recovery.
Early diagnosis, discontinuation of the drug, and supportive
care will lead to a successful recovery in the majority of cases.
Rechallenge should always be avoided.
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